AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03716518
Drug: Placebo of 'Tonifying Spleen and Kidney Sequential Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of TCM-TSKSR will be given to the participants as follows:placebo of Liu-jun-an-wei Granule,1 pack each time,twice a day,PO,from 0 to 6th day of chemotherapy and placebo of Qi-tu-er-zhi Granule,1 pack each time,twice a day,from 7th to 20th day of chemotherapy.
Trial: NCT04350736
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to be administered by inhalation
Trial: NCT05529290
Drug: Dexketoprofen Trometamol + Thiocolchicoside
RxNorm normalized name: dexketoprofen trometamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexketoprofen Trometamol + Thiocolchicoside (25mg + 4mg) is a NSAID. It was given to the patients twice a day.
Trial: NCT05529290
Drug: Dexketoprofen Trometamol + Paracetamol
RxNorm normalized name: dexketoprofen trometamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexketoprofen Trometamol + Paracetamol (25mg + 300mg) is a NSAID. It was given to the patients twice a day.
Trial: NCT05529290
Drug: Dexketoprofen Trometamol (25mg)
RxNorm normalized name: dexketoprofen trometamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexketoprofen Trometamol (25mg) is a NSAID. It was given to the patients twice a day.
Trial: NCT01762306
Drug: Diclofenac Potassium
RxNorm normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02702011
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04325776
Drug: AL2846
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AL2846 is a multi-target tyrosine kinase receptor inhibitor with obvious selective to c-met.
Trial: NCT04325776
Drug: Zoledronic Acid Injection
RxNorm normalized name: zoledronic acid Injection
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid is a bisphosphonate drug that has a strong inhibition of bone resorption and a potential to promote bone formation, and can be used for bone metastasis caused by malignant tumors.
Trial: NCT01640990
Drug: GW328267X (total dose of 12mcg)
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mcg/h for 1.5 hours (total dose of 12mcg)
Trial: NCT01640990
Drug: GW328267X (total dose of 40mcg)
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mcg/h for 4 hours (total dose of 40 mcg)
Trial: NCT01179347
Drug: Placebo Respimat® inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patient to receive placebo matching active drug once daily
Trial: NCT01985373
Drug: Intravenous immunoglobulin infusion
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood samples are drawn before infusion with Nanogam 50 and Nanogam 100 mg/ml and IgG levels are determined to study PK
Trial: NCT00825019
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration in 12h intervals
Trial: NCT00852189
Drug: EC0489, Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PART B: Once PART A MTD is determined, PART B will begin. Dose escalation from a starting dose of 4.2 mg/m2 IV bolus once weekly in a 4-week cycle to the Maximum Tolerated Dose (MTD).
Trial: NCT00574119
Drug: spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: spironolactone 50 mg daily for 6 months
Trial: NCT03379506
Drug: EBR/GZR FDC Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who are 12 to \<18 years of age will receive oral FDC tablets with EBR 50 mg/GZR 100 mg once daily by mouth.
Trial: NCT03379506
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet matched to EBR/GZR FDC tablet.
Trial: NCT00020566
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00600028
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 50-100 mg by mouth per day
Trial: NCT01925612
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
Trial: NCT01925612
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
Trial: NCT01969669
Drug: ABT-199
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with ketoconazole
Trial: NCT00031499
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single 2 gram oral dose (4 tablets) at Day 1.
Trial: NCT00031499
Drug: Benzathine Penicillin
RxNorm normalized name: Benzathine penicillin G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplied in pre-filled syringes containing 1.2 million units of benzathine penicillin; 2.4 million units administered intramuscularly at Day 1, in one or both buttocks.
Trial: NCT00031499
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Baseline visit, 28 capsules dispensed, for a dose of 100 mg twice a day (BID).
Trial: NCT02831842
Drug: Anti-EGFR-Containing Regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study protocol does not specify any particular chemotherapy regimen. The data will be collected retrospectively.
Trial: NCT02831842
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study protocol does not specify any particular chemotherapy regimen. The data will be collected retrospectively.
Trial: NCT01216449
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 250mL of 0.9% sodium chloride solution, infused over 30 minutes
Trial: NCT03325556
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, tablets, once daily by mouth
Trial: NCT00900445
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT02603354
Drug: peroxide gel tooth bleaching 6%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gel of hygrogen peroxide for teeth bleaching in a low concentration (6%)
Trial: NCT01082367
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03934710
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug will be administered in solution form
Trial: NCT00348413
Drug: Intravenous Methylprednisolone + Oral Methotrexate vs Intravenous Methylprednisolone + Placebo
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00303758
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00303758
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01662687
Drug: Kytril inj.+Kytril tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients were randomized to Sancuso patch or Kytril groups and received the assigned treatment for 4days.~Active Comparator arm:~* Kytril inj. 3mg: administered by intravenous infusion at least 5 minutes, just before the first chemotherapy (Day 1).~* Kytril tab. 1mg: administered twice a day by orally at Day 2\~4.
Trial: NCT01037452
Drug: Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT01261546
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 0,6 ml/kg, IV, q.i.d. for 2 days.~* Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present.~* Ranitidine 5 mg/kg IV, q.d. for 2 days.~* Amoxicillin- Clavulanic acid 80mg/kg p.o., q.d. during 15 days.
Trial: NCT04184115
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Nasal Gel and placebo patch
Trial: NCT02976727
Drug: Placebo cream application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo cream (indistinguishable from calcipotriol cream by visual and physical appearance and sense of smell) was applied twice for daily on treatment area for 15 consecutive days.
Trial: NCT02976727
Drug: MAL application
RxNorm normalized name: maleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediately after AFL treatment, an approximately 1- mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. Incubation time is 3 hours
Trial: NCT01037452
Drug: Calcium carbonate/magnesium hydroxide
RxNorm normalized name: CALCIUM CARBONATE/MAGNESIUM HYDROXIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT01037452
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT03410927
Drug: TAS0728
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAS0728 is an oral HER2 covalent inhibitor investigated in patients with advanced solid tumor harboring HER2 or HER3 abnormalities. It will be administered orally at a starting dose of 50 mg BID each morning and evening and escalated to the DLT. The MTD will be used for the phase 2 arms of the study.
Trial: NCT01763463
Drug: New users of ADVAIR DISKUS, ADVAIR HFA (ICS) - containing medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be considered a new user of ICS-containing medications if they had not received a prescription for an ICS-containing medication in the year prior to cohort entry. ICS-containing medications could include ICS and ICS/LABA fixed dose combinations combinations. Patients could not use LABD (long-acting beta-agonists and long-acting antimuscarinics) in the year prior or initiate triple therapy (e.g., ICS/LABA/LAMA) as their new user prescription.
Trial: NCT01763463
Drug: New users of FLOVENT DISKUS, FLVENT HFA (long-acting bronchodilators (LABD))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be considered a new user of LABD medications (long-acting beta-agonists or long-acting antimuscarinics but not both) if they had not received a prescription for an LABD medication in the year prior to cohort entry. Patients could not use ICS-containing medications in the year prior to their new use of LABD or initiate triple therapy (e.g., ICS/LABA/LAMA) as their new user prescription.
Trial: NCT02967094
Drug: Administration of mucolytic solution before upper endoscopy (Espumisan, ACC long)
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04324918
Drug: HCP1102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants will receive tretment of HCP1102(combination of Montelukast + Levocetrizine), orally, once daily for 4weeks.
Trial: NCT04324918
Drug: HGP1408
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants will receive tretment of HGP1408(Levocetrizine), orally, once daily for 4weeks.
Trial: NCT03897868
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01309841
Drug: NKTR-118
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg oral tablet once daily
Trial: NCT01309841
Drug: NKTR-118
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg oral tablet once daily
Trial: NCT01309841
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet once daily
Trial: NCT02119234
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02407041
Drug: GR-MD-02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT00213161
Drug: iron supplement, iron drops
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01259973
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 single dose of 2.5mL physiological serum masked in 250 mL of peach juice, for 1 day. Oral administration.
Trial: NCT01374217
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin will be administered as it was prior to study entry.
Trial: NCT01011452
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 placebo capsule at study entry and a further placebo capsule at 10pm for four weeks
Trial: NCT03428685
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebos will be prescribed from 12 - 36+6 weeks.
Trial: NCT02486211
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT02781454
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00673894
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamine 30g +placebo (matching sitagliptin 100 mg)
Trial: NCT04309669
Drug: TOT'HEMA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: three ampoules per day during 12 weeks
Trial: NCT00493974
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 4 x daily
Trial: NCT00326417
Drug: Cyclophosphamide 150mg
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A total dose of 150 mg/kg will be given as 50 mg/kg per day for 3 days (Days -4, -3, -2)
Trial: NCT00326417
Drug: Cyclophosphamide 100mg
RxNorm normalized name: CYCLOPHOSPHAMIDE 100MG/VIL INJ
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A total dose of 100 mg/kg will be given as 50 mg/kg per day for 2 days (Days -3, -2)
Trial: NCT00326417
Drug: Cyclophosphamide 50mg
RxNorm normalized name: CYCLOPHOSPHAMIDE 50MG TAB
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A total dose of 50 mg/kg will be given once at 50 mg/kg per day on Day -2
Trial: NCT04367441
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: auxiliary material of 608 include histidine, histidine hydrochloride, sucrose and polysorbate 80
Trial: NCT01213368
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablets~Route of administration: oral
Trial: NCT02183623
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00405821
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet twice daily for 24 months
Trial: NCT03896113
Drug: Celecoxib 200mg capsule
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient confirmed with endometrial cancer will received twice daily 200 mg Celecoxib, 15 days before the surgery.
Trial: NCT00835419
Drug: P276-00
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P276-00 -small molecule Cdk 4-D1, Cdk1-B and Cdk9-T inhibitor
Trial: NCT01283997
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg by mouth for 1 dose, then 100 mg by mouth every 12 hours for 10 weeks.
Trial: NCT01116687
Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT01825980
Drug: BZF961
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There will be 2 parts to the study: Part 1: BZF monotherapy. Part 2: Cohort IIa: BZF961 monotherapy at 3 TBD doses; Cohort IIb: BZF961 in combination with ritonavir at TBD doses.
Trial: NCT01825980
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00673686
Drug: Yasminelle (SH T 00186 D)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SH T 00186 D in a 21-day regimen, i.e., 21 verum tablets, 7 placebo tablets Dose: 0.02 mg EE, 3 mg DRSPMode of administration: Oral, 1 tablet dailyDuration of treatment: 3 cycles of 28 days each
Trial: NCT01615796
Drug: Part A: GSK2140944 Drug single dose of 200mg, 600mg, 1200mg, 1800 mg, and dose to be determined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receive a single dose of GSK2140944
Trial: NCT01615796
Drug: Part B: GSK2140944 Repeat Drug dose of 400mg, 750mg, 1000 mg, and dose to be determined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive repeat doses of GSK2140944 BID/TID for up to 14 Days
Trial: NCT03520439
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Placebo Oral Tablet 1# (first menstrual third days), 1 times a day, 12 weeks, fasting or taking 2 hours after eating
Trial: NCT03117530
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Following initial baseline PET-CT imaging and clinical evaluation, adults with ASD will undergo a 12- week open-label treatment trial of minocycline to be conducted at UCLA under supervision of the UCLA IRB. During weeks 1-6, ASD subjects will be treated with 50 mg minocycline twice daily (low dose). From weeks 7-12, dosing will be increased to 100mg twice daily (typical clinical dosage). Every two weeks during this phase, a treating clinician will measure vital signs, assess safety, record adverse effects, and monitor compliance. Compliance will be obtained as an index of tolerability and will assessed through weekly medication diaries and pill counts.
Trial: NCT02592395
Drug: FOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The chemotherapy schedule will include administration of FOLFIRINOX (5-Fluorouracil, Irinotecan, Oxaliplatin, and Leucovorin) will be:~Day 1: Oxaliplatin at 85mg/m2 over 120 minutes, Irinotecan 180mg/m2 over 90 minutes, Leucovorin 400mg/m2 over 90minutes, 5-Fluorouracil (5-FU) 1200mg/m2/day continuous infusion (CIV) over 46 hours. Day 3: 5-FU CIV pump will be disconnected. Neulasta injection 6mg subcutaneous
Trial: NCT00880763
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to vaniprevir oral capsule twice daily for 28 days
Trial: NCT00267371
Drug: Medical management/current medications per standard of care by personal physician.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical management with current medications per standard of care by personal physician.
Trial: NCT00253318
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg orally on Days 1 and 8.
Trial: NCT00905723
Drug: estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg daily for 6 months
Trial: NCT00905723
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugar pill daily for six months
Trial: NCT04157868
Drug: rhBNP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhBNP intra-coronary injection 1.5 ug/kg loading dose, with intravenous injection 0.0075-0.01 ug/kg/min persistent for 72 hour.
Trial: NCT00839423
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules, daily, orally
Trial: NCT00003194
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04733001
Drug: HSG4112
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily oral administration
Trial: NCT01188525
Drug: 10 parents drugs adminstration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single and concomittant administration of 10 parent drugs will be performed: Acetaminophene, cafeine, dextrometorphan, digoxin, memantine,midazolam, omeprazole, repaglinide, rosuvastatine, tolbutamide.
Trial: NCT00980785
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT02924688
Drug: FF/UMEC/VI (100/31.25/25) mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry white powder delivered via the ELLIPTA DPI (one inhalation once-daily \[QD\] in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 31.25 mcg and VI 25 mcg in each blister.
Trial: NCT02924688
Drug: FF/UMEC/VI (100/62.5/25) mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister.
Trial: NCT02924688
Drug: FF/UMEC/VI (200/31.25/25) mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains UMEC 31.25 mcg and VI 25 mcg in each blister.
Trial: NCT02924688
Drug: FF/UMEC/VI (200/62.5/25) mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister.